Thomas Perkmann is an expert in Immunology at Medical University of Vienna (Austria). Thomas Perkmann has authored 181 publications, the most recent in 2026, and is an investigator in 8 clinical trials. SLR score: 481 (community average: 125). How the SLR is computed.

LeadR Profile

Thomas Perkmann Medical University of Vienna Austria
481 ScienceLeadR Reputation 481
Network Map

Immunology

Subspecialties: Pulmonology - Cardiology - Hepatology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2005 - 2026

Source: PubMed

Medical University of Vienna

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 181

Citations

Citations: 6 207 1st author: 13 Last author: 2 Unique author: 0


Best Journals

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Routine laboratory data are decoupled from symptom phenotype and prognosis in Long COVID: within-cohort variation is dominated by age.
PMID 42861769 — research design, laboratories, phenotype, cluster analysis, latent class analysis, prognosis, post-acute covid-19 syndrome
Clin Chem Lab Med20260
Circulating fibronectin levels are linked to liver function, matrix remodeling, and hemostatic complications in advanced chronic liver disease.
PMID 42789231 — liver diseases, hemorrhage, hemostatics, portal vein, liver, fibronectins, thrombosis, veins, cholinesterases
Hepatol Int20260
Relation of nailfold capillaries and autoantibodies to mortality in patients with Raynaud's phenomenon: a retrospective analysis.
PMID 42550247 — autoantibodies, rheumatology, mortality, capillaries, antibodies
Rheumatol Int20261
Impact of ABO Blood System on Immunogenicity and Vaccine Efficacy of COVID-19 Booster Vaccination-A Population-Based Study of 3066 Individuals.
PMID 42524760 — antibody formation, blood, vaccines, antibodies, antibodies, neutralizing, vaccination, covid-19, influenza, human, infections, vaccine efficacy, breakthrough infections
Influenza Other Respir Viruses20260
Utilization Patterns of Hospital Biobank Samples: Time to First Use and Material-Specific Demand.
PMID 42279153 — plasma
J Clin Med20262

Clinical Studies 8

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

N/A 5
Phase 2 1
Phase 3 1
Phase 4 1

By status:

Completed 4
Unknown 3
Recruiting 1

By type:

Interventional 5
Observational 3

By Monocentric/Multicentric:

monocentric 7
multicentric2to4 0
multicentric5to9 1
multicentricup10 0

Main Topics

LeadR Networks

Main global connection map